Premium
Etanercept Treatment in Myasthenia Gravis
Author(s) -
Rowin Julie
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1405.028
Subject(s) - etanercept , medicine , myasthenia gravis , rheumatoid arthritis , ankylosing spondylitis , psoriasis , tumor necrosis factor alpha , psoriatic arthritis , spondylitis , immunology , dermatology
Etanercept is a tumor necrosis factor (TNF) blocking agent that has been shown to suppress ongoing experimental autoimmune myasthenia gravis (EAMG). This subcutaneously administered TNF blocking agent has also been shown to be safe and effective in several rheumatological diseases including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. A prospective clinical pilot trial of etanercept in corticosteroid‐dependent autoimmune myasthenia gravis (MG) patients supports further study into etanercept as a treatment for MG.